首页> 美国卫生研究院文献>Journal of Visualized Experiments : JoVE >Killer Artificial Antigen Presenting Cells (KaAPC) for Efficient In Vitro Depletion of Human Antigen-specific T Cells
【2h】

Killer Artificial Antigen Presenting Cells (KaAPC) for Efficient In Vitro Depletion of Human Antigen-specific T Cells

机译:高效人工耗竭人类抗原特异性T细胞的杀手性人工抗原呈递细胞(KaAPC)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Current treatment of T cell mediated autoimmune diseases relies mostly on strategies of global immunosuppression, which, in the long term, is accompanied by adverse side effects such as a reduced ability to control infections or malignancies. Therefore, new approaches need to be developed that target only the disease mediating cells and leave the remaining immune system intact. Over the past decade a variety of cell based immunotherapy strategies to modulate T cell mediated immune responses have been developed. Most of these approaches rely on tolerance-inducing antigen presenting cells (APC). However, in addition to being technically difficult and cumbersome, such cell-based approaches are highly sensitive to cytotoxic T cell responses, which limits their therapeutic capacity. Here we present a protocol for the generation of non-cellular killer artificial antigen presenting cells (KaAPC), which allows for the depletion of pathologic T cells while leaving the remaining immune system untouched and functional. KaAPC is an alternative solution to cellular immunotherapy which has potential for treating autoimmune diseases and allograft rejections by regulating undesirable T cell responses in an antigen specific fashion.
机译:T细胞介导的自身免疫疾病的当前治疗主要依赖于整体免疫抑制的策略,从长远来看,它伴随着不良的副作用,例如降低了控制感染或恶性肿瘤的能力。因此,需要开发仅靶向疾病介导细胞并保持剩余免疫系统完整的新方法。在过去的十年中,已经开发了多种基于细胞的免疫疗法来调节T细胞介导的免疫反应。这些方法大多数依赖于诱导耐受性的抗原呈递细胞(APC)。然而,除了技术上困难和麻烦之外,这种基于细胞的方法对细胞毒性T细胞应答高度敏感,这限制了它们的治疗能力。在这里,我们提出了一种用于生成非细胞杀伤性人工抗原呈递细胞(KaAPC)的协议,该协议可消除病理性T细胞,同时保持其余免疫系统不受影响和发挥功能。 KaAPC是细胞免疫疗法的替代解决方案,它具有通过以抗原特异性方式调节不良T细胞反应来治疗自身免疫性疾病和同种异体移植排斥的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号